Department of Medical Oncology, Clinical Medical College, Yangzhou University, Yangzhou City, Jiangsu Province, China.
Department of Thoracic Surgery, Clinical Medical College, Yangzhou University, Yangzhou City, Jiangsu Province, China.
J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):919-929. doi: 10.1016/j.jvsv.2020.01.010. Epub 2020 Mar 21.
Peripherally inserted central venous catheter (PICC)-related thrombosis (PRT) is a serious complication that can lead to interruptions in chemotherapy and other supportive care, as well as increased hospital stay and costs. We conducted a retrospective study to evaluate the patterns of symptomatic PRT in patients with cancer undergoing chemotherapy and their risk factors.
A retrospective study of 938 PICC patients from our institution between November 2014 and July 2017 was performed. Symptomatic PRT events were confirmed by color Doppler ultrasonography or computed tomography pulmonary angiography in the presence of clinical symptoms. The variables of interest were extracted from the electronic medical record system. Logistic regression analysis was used to determine the risk factors for PRT.
Of the 938 patients who were followed up for more than 120,000 patient-days, 63 patients (6.7%; 0.51 per 1000 catheter-days) had symptomatic PRT. Sixty-one patients were diagnosed with upper extremity venous thrombosis (UEVT), of which 18 were isolated superficial vein thrombosis (SVT), 19 were isolated deep vein thrombosis (DVT), and 24 were extensive venous thrombosis (EVT). Two patients were diagnosed with pulmonary embolism, and two patients were diagnosed with UEVT with pulmonary embolism. The symptomatic SVT occurred in 42 of 938 patients with cancer (4.5%), which accounted for 68.9% of all UEVT events. The median time to PRT was 21 days, and the median time to catheter removal in the PRT group was 66 days as compared with 117 days in the no PRT group. Predictors associated with increased risk of PRT were age >60 years (odds ratio [OR], 2.142; 95% confidence interval [CI], 1.118-4.103) and a chemotherapy regimen containing fluorouracil (OR, 2.429; 95% CI, 1.013-5.825). Hypertension with medication was a protective factor for PRT (OR, 0.306; 95% CI, 0.113-0.828). Among the 28 patients who did not remove their PICCs immediately after PRT was diagnosed, patients with SVT, DVT, and EVT had similar success rates of retaining catheters in situ after anticoagulant therapy (SVT, 83.3%; DVT, 62.5%; EVT, 75.0%; P = .667).
Age >60 years and chemotherapy regimens containing fluorouracil were independent risk factors for PRT and hypertension with medication was associated with a lower risk of PRT in patients with cancer with PICCs receiving chemotherapy. PICCs-related SVT was a frequent type of PRT, which might need a better understanding and anticoagulant therapy in patients with cancer with PICCs.
经外周静脉置入中心静脉导管(PICC)相关性血栓形成(PRT)是一种严重的并发症,可导致化疗及其他支持性治疗中断,增加住院时间和费用。我们进行了一项回顾性研究,以评估接受化疗的癌症患者中出现有症状的 PRT 及其危险因素。
对 2014 年 11 月至 2017 年 7 月我院 938 例 PICC 患者进行回顾性研究。有临床症状的患者,通过彩色多普勒超声或计算机断层肺动脉造影(CTPA)检查来确诊有症状的 PRT 事件。从电子病历系统中提取感兴趣的变量。采用 logistic 回归分析确定 PRT 的危险因素。
938 例患者随访超过 120000 个患者日,其中 63 例(6.7%;0.51/1000 导管日)发生有症状的 PRT。61 例诊断为上肢静脉血栓形成(UEVT),其中 18 例为单纯浅静脉血栓形成(SVT),19 例为单纯深静脉血栓形成(DVT),24 例为广泛静脉血栓形成(EVT)。2 例患者诊断为肺栓塞,2 例患者诊断为 UEVT 合并肺栓塞。42 例癌症患者(4.5%)出现有症状的 SVT,占所有 UEVT 事件的 68.9%。PRT 的中位时间为 21 天,PRT 组的导管拔除中位时间为 66 天,而无 PRT 组为 117 天。与 PRT 风险增加相关的预测因素为年龄>60 岁(比值比 [OR],2.142;95%置信区间 [CI],1.118-4.103)和含有氟尿嘧啶的化疗方案(OR,2.429;95%CI,1.013-5.825)。有药物治疗的高血压是 PRT 的保护因素(OR,0.306;95%CI,0.113-0.828)。在 28 例 PRT 确诊后未立即拔除 PICC 的患者中,SVT、DVT 和 EVT 患者在抗凝治疗后保留导管原位的成功率相似(SVT,83.3%;DVT,62.5%;EVT,75.0%;P=0.667)。
年龄>60 岁和含有氟尿嘧啶的化疗方案是 PRT 的独立危险因素,有药物治疗的高血压与癌症患者接受化疗时 PRT 的风险较低相关。PICC 相关性 SVT 是 PRT 的常见类型,可能需要更好地了解和抗凝治疗。